{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:48:38Z","timestamp":1777632518637,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid progression and poor prognosis. This study integrates bioinformatics with experimental validation to characterize the role of Frizzled-3 (FZD3), a Wnt receptor, in SCLC progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed transcriptomic data from 102 SCLC and 55 normal lung tissues retrieved from the Gene Expression Omnibus (datasets GSE6044, GSE40275, and GSE60052). Differential expression analysis was performed using the limma package, followed by GO and KEGG pathway enrichment analyses. To screen for robust prognostic markers, we employed machine learning algorithms\u2014specifically LASSO and Random Forest\u2014to select hub genes. The prognostic significance of FZD3 was assessed using multivariate Cox regression and Kaplan-Meier survival analysis. Validation assays, including qRT-PCR, Western blotting, and functional assays (proliferation, migration, invasion, and apoptosis), were conducted in SCLC cell lines and clinical specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,192 differentially expressed genes were identified. Enrichment analysis revealed significant involvement in immune-related pathways and Wnt signaling. FZD3 was selected as a key hub gene and found to be upregulated in SCLC tissues and cell lines. High FZD3 expression was correlated with advanced clinical stage(by Kruskal-Wallis test), and poor prognosis (by Survival analysis). In vitro function assays demonstrated that FZD3 knockdown significantly attenuated SCLC cell proliferation, migration, and invasion while inducing apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FZD3 is frequently overexpressed in SCLC and serves as an independent prognostic indicator for poor survival. Our findings elucidate the oncogenic role of FZD3 in SCLC, highlighting its potential as a therapeutic target and prognostic biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03634-1","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:44:47Z","timestamp":1774057487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Wnt receptor Frizzled3 (FZD3) drives aggressive phenotypes in small cell lung cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Mingjun","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"3","key":"3634_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3634_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3634_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3634_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol. 2023;18(1):31\u201346.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"3634_CR5","first-page":"1906","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: Rev JAMA. 2025;333(21):1906\u201317.","journal-title":"Small Cell Lung Cancer: Rev JAMA"},{"issue":"12","key":"3634_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332.","journal-title":"JAMA Oncol"},{"issue":"7","key":"3634_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/0109298665315841240731060636","volume":"31","author":"X Deng","year":"2024","unstructured":"Deng X, et al. The Role of TGFBR3 in the Development of Lung Cancer. Protein Pept Lett. 2024;31(7):491\u2013503.","journal-title":"Protein Pept Lett"},{"issue":"1","key":"3634_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1183\/09031936.00105009","volume":"35","author":"IK Demedts","year":"2010","unstructured":"Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J. 2010;35(1):202\u201315.","journal-title":"Eur Respir J"},{"key":"3634_CR9","doi-asserted-by":"crossref","unstructured":"Drapkin BJ, Rudin CM. Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harb Perspect Med, 2021; 11(4).","DOI":"10.1101\/cshperspect.a038240"},{"issue":"1","key":"3634_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","volume":"18","author":"X Zhai","year":"2025","unstructured":"Zhai X, et al. Current and future therapies for small cell lung carcinoma. J Hematol Oncol. 2025;18(1):37.","journal-title":"J Hematol Oncol"},{"issue":"7563","key":"3634_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47\u201353.","journal-title":"Nature"},{"issue":"4","key":"3634_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s13402-024-00941-x","volume":"47","author":"M Lu","year":"2024","unstructured":"Lu M, et al. The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells. Cell Oncol (Dordr). 2024;47(4):1497\u2013502.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"3634_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","volume":"19","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, et al. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024;19(6):879\u201392.","journal-title":"Target Oncol"},{"issue":"6","key":"3634_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.chest.2018.07.029","volume":"154","author":"A Thomas","year":"2018","unstructured":"Thomas A, et al. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. Chest. 2018;154(6):1284\u201390.","journal-title":"Chest"},{"issue":"24","key":"3634_CR15","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","volume":"20","author":"S Sundstr\u00f8m","year":"2002","unstructured":"Sundstr\u00f8m S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up. J Clin Oncol. 2002;20(24):4665\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3634_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","volume":"10","author":"BJ Roth","year":"1992","unstructured":"Roth BJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10(2):282\u201391.","journal-title":"J Clin Oncol"},{"issue":"23","key":"3634_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"key":"3634_CR18","doi-asserted-by":"crossref","unstructured":"Dolkar T et al. New developments in immunotherapy for SCLC. J Immunother Cancer, 2025;13(1).","DOI":"10.1136\/jitc-2024-009667"},{"issue":"6","key":"3634_CR19","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s43018-025-00992-5","volume":"6","author":"K Qin","year":"2025","unstructured":"Qin K, et al. The current and emerging immunotherapy paradigm in small-cell lung cancer. Nat Cancer. 2025;6(6):954\u201366.","journal-title":"Nat Cancer"},{"issue":"5","key":"3634_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021;27(5):1526\u201337.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3634_CR21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893\u2013903.","journal-title":"J Clin Oncol"},{"key":"3634_CR22","doi-asserted-by":"crossref","unstructured":"Beg A, Parveen R. Chap. 11 - Role of Bioinformatics in cancer research and drug development. Translational Bioinformatics in Healthcare and Medicine. Academic; K. Raza and N. Dey, Editors. 2021: 141\u20138.","DOI":"10.1016\/B978-0-323-89824-9.00011-2"},{"issue":"2","key":"3634_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2796.2011.02498.x","volume":"271","author":"Q Tian","year":"2012","unstructured":"Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med. 2012;271(2):111\u201321.","journal-title":"J Intern Med"},{"key":"3634_CR24","doi-asserted-by":"crossref","unstructured":"Cancer Bioinformatics: From Therapy Design to Treatment Edited by Nagl S. Biometrics, 2006; 62(4): 1280\u20131280.","DOI":"10.1111\/j.1541-0420.2006.00596_16.x"},{"issue":"3","key":"3634_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nbt0308-303","volume":"26","author":"M Ringn\u00e9r","year":"2008","unstructured":"Ringn\u00e9r M. What is principal component analysis? Nat Biotechnol. 2008;26(3):303\u20134.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"3634_CR26","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3634_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284\u20137.","journal-title":"Omics"},{"key":"3634_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.proeng.2017.09.615","volume":"201","author":"LE Melkumova","year":"2017","unstructured":"Melkumova LE, Shatskikh SY. Comparing Ridge and LASSO estimators for data analysis. Procedia Eng. 2017;201:746\u201355.","journal-title":"Procedia Eng"},{"key":"3634_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1476-4598-9-212","volume":"9","author":"SS Kanwar","year":"2010","unstructured":"Kanwar SS, et al. The Wnt\/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer. 2010;9:212.","journal-title":"Mol Cancer"},{"issue":"5","key":"3634_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"5","key":"3634_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534\u201340.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"3634_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1089\/aid.1992.8.1699","volume":"8","author":"SE Macatonia","year":"1992","unstructured":"Macatonia SE, et al. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res Hum Retroviruses. 1992;8(9):1699\u2013706.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"3634_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1006\/viro.1993.1451","volume":"196","author":"Y Koyanagi","year":"1993","unstructured":"Koyanagi Y, et al. In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology. 1993;196(1):25\u201333.","journal-title":"Virology"},{"issue":"4","key":"3634_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm1745","volume":"14","author":"KS Jones","year":"2008","unstructured":"Jones KS, et al. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008;14(4):429\u201336.","journal-title":"Nat Med"},{"issue":"4","key":"3634_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","volume":"1802","author":"EK Kim","year":"2010","unstructured":"Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396\u2013405.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"3634_CR36","doi-asserted-by":"publisher","first-page":"e26999","DOI":"10.1371\/journal.pone.0026999","volume":"6","author":"M Li","year":"2011","unstructured":"Li M, Liu J, Zhang C. Evolutionary history of the vertebrate mitogen activated protein kinases family. PLoS ONE. 2011;6(10):e26999.","journal-title":"PLoS ONE"},{"issue":"8","key":"3634_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","volume":"1773","author":"M Katz","year":"2007","unstructured":"Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007;1773(8):1161\u201376.","journal-title":"Biochim Biophys Acta"},{"key":"3634_CR38","doi-asserted-by":"crossref","unstructured":"Paton EL, Turner JA, Schlaepfer IR. Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. J Oncol, 2020. 2020: 1079827.","DOI":"10.1155\/2020\/1079827"},{"issue":"7","key":"3634_CR39","doi-asserted-by":"publisher","first-page":"e0179726","DOI":"10.1371\/journal.pone.0179726","volume":"12","author":"NO Siemers","year":"2017","unstructured":"Siemers NO, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE. 2017;12(7):e0179726.","journal-title":"PLoS ONE"},{"key":"3634_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2019.05.007","volume":"457","author":"D Mo","year":"2019","unstructured":"Mo D, et al. A tRNA fragment, 5\u2019-tiRNA(Val), suppresses the Wnt\/\u03b2-catenin signaling pathway by targeting FZD3 in breast cancer. Cancer Lett. 2019;457:60\u201373.","journal-title":"Cancer Lett"},{"key":"3634_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.omtn.2020.10.010","volume":"22","author":"S Zhu","year":"2020","unstructured":"Zhu S, et al. lncRNA SNHG10 Promotes the Proliferation and Invasion of Osteosarcoma via Wnt\/\u03b2-Catenin Signaling. Mol Ther Nucleic Acids. 2020;22:957\u201370.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"13","key":"3634_CR42","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.7150\/ijbs.62858","volume":"17","author":"SZ Li","year":"2021","unstructured":"Li SZ, et al. miR-139\/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt\/\u03b2-catenin signaling. Int J Biol Sci. 2021;17(13):3508\u201321.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"3634_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1055-9965.EPI-15-0834","volume":"25","author":"MA Hildebrandt","year":"2016","unstructured":"Hildebrandt MA, et al. Germline Genetic Variants in the Wnt\/\u03b2-Catenin Pathway as Predictors of Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2016;25(3):540\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"3634_CR44","doi-asserted-by":"publisher","first-page":"109431","DOI":"10.1016\/j.celrep.2021.109431","volume":"36","author":"Z Chen","year":"2021","unstructured":"Chen Z, et al. Identification of cis-HOX-HOXC10 axis as a therapeutic target for colorectal tumor-initiating cells without APC mutations. Cell Rep. 2021;36(4):109431.","journal-title":"Cell Rep"},{"key":"3634_CR45","doi-asserted-by":"publisher","first-page":"p10936","DOI":"10.1038\/ncomms10936","volume":"7","author":"W Wang","year":"2016","unstructured":"Wang W, et al. Feedback regulation of apical progenitor fate by immature neurons through Wnt7-Celsr3-Fzd3 signalling. Nat Commun. 2016;7:p10936.","journal-title":"Nat Commun"},{"issue":"1","key":"3634_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuron.2014.05.037","volume":"83","author":"M Simonetti","year":"2014","unstructured":"Simonetti M, et al. Wnt-Fzd signaling sensitizes peripheral sensory neurons via distinct noncanonical pathways. Neuron. 2014;83(1):104\u201321.","journal-title":"Neuron"},{"issue":"10","key":"3634_CR47","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.1813802116","volume":"116","author":"C Li","year":"2019","unstructured":"Li C, et al. Down-regulation of FZD3 receptor suppresses growth and metastasis of human melanoma independently of canonical WNT signaling. Proc Natl Acad Sci USA. 2019;116(10):4548\u201357.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3634_CR48","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1038\/s41467-024-51451-1","volume":"15","author":"J Hillier","year":"2024","unstructured":"Hillier J, et al. Structural insights into Frizzled3 through nanobody modulators. Nat Commun. 2024;15(1):7228.","journal-title":"Nat Commun"},{"issue":"1","key":"3634_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41421-023-00627-y","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. A framework for Frizzled-G protein coupling and implications to the PCP signaling pathways. Cell Discov. 2024;10(1):3.","journal-title":"Cell Discov"},{"key":"3634_CR50","doi-asserted-by":"publisher","first-page":"1676414","DOI":"10.3389\/fonc.2025.1676414","volume":"15","author":"J Cai","year":"2025","unstructured":"Cai J, et al. PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age. Front Oncol. 2025;15:1676414.","journal-title":"Front Oncol"},{"key":"3634_CR51","doi-asserted-by":"crossref","unstructured":"Hmila I, Katanaev VL. Therapeutic targeting of FZD receptor proteins with biologics in cancer. Drug Discov Today, 2026: 104621.","DOI":"10.1016\/j.drudis.2026.104621"},{"issue":"7","key":"3634_CR52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/1120009X.2023.2182573","volume":"35","author":"Z Meng","year":"2023","unstructured":"Meng Z, et al. Frizzled-3 suppression overcomes multidrug chemoresistance by Wnt\/\u03b2-catenin signaling pathway inhibition in hepatocellular carcinoma cells. J Chemother. 2023;35(7):653\u201361.","journal-title":"J Chemother"},{"key":"3634_CR53","doi-asserted-by":"crossref","unstructured":"Li Y, et al. Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer. Oncogene. 2025;44(50):4868\u201377.","DOI":"10.1038\/s41388-025-03631-6"},{"key":"3634_CR54","doi-asserted-by":"crossref","unstructured":"Wagner AH, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun. 2018;9(1):3787.","DOI":"10.1038\/s41467-018-06162-9"},{"key":"3634_CR55","doi-asserted-by":"crossref","unstructured":"Yang J, et al. Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a\/PKC Signaling Pathway. Stem Cells Int. 2016;2016:1690896.","DOI":"10.1155\/2016\/1690896"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03634-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03634-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:08:17Z","timestamp":1777435697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03634-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3634"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03634-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical guidelines and research protocol of Beijing Chest Hospital (Approval Number: LW-2024-022). Ethical approval for the study was obtained following a comprehensive review by the ethics committee of Beijing Chest Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}